These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 18278207

  • 1. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H.
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [Abstract] [Full Text] [Related]

  • 2. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
    Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, Schicha H.
    Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O, Schulz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohmen BM, Bares R, Büll U.
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [Abstract] [Full Text] [Related]

  • 5. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
    Guhlmann CA, Rendl J, Börner W.
    Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
    [Abstract] [Full Text] [Related]

  • 6. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D, Epstein M, Lan L, Tan P, Booker J.
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [Abstract] [Full Text] [Related]

  • 7. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L, De Palma D, Ceriani L, Vanoli P, Garancini S, Tordiglione M, Tarolo GL.
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [Abstract] [Full Text] [Related]

  • 8. [Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses].
    Moser E, Pickardt CR, Mann K, Engelhardt D, Kirsch CM, Knesewitsch P, Tatsch K, Kreisig T, Kurz C, Saller B.
    Nuklearmedizin; 1988 Jun; 27(3):98-104. PubMed ID: 3405782
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A, Malabu UH, El-Desouki MI, Al-Rubeaan KA, Al-Ruhaily AD, Fouda MA, Al-Maatouq MA, Sulimani RA.
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [Abstract] [Full Text] [Related]

  • 11. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H.
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [Abstract] [Full Text] [Related]

  • 12. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
    Róka R, Séra T, Valkusz Z, Julesz J, Csernay L, Pávics L.
    Orv Hetil; 1999 Jun 06; 140(23):1291-5. PubMed ID: 10412264
    [Abstract] [Full Text] [Related]

  • 13. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
    Schneider P, Körber C, Körber-Hafner N, Hänscheid H, Reiners C.
    Nuklearmedizin; 2002 Dec 06; 41(6):240-4. PubMed ID: 12520660
    [Abstract] [Full Text] [Related]

  • 14. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.
    Nuklearmedizin; 2007 Dec 06; 46(3):77-84. PubMed ID: 17549318
    [Abstract] [Full Text] [Related]

  • 15. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M, Sowiński J, Dolata M, Junik R, Gembicki M, Skiba A.
    Nucl Med Rev Cent East Eur; 2005 Dec 06; 8(1):28-32. PubMed ID: 15977144
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J.
    Clin Endocrinol (Oxf); 2004 Nov 06; 61(5):641-8. PubMed ID: 15521969
    [Abstract] [Full Text] [Related]

  • 17. [Results of radioiodine therapy in different forms of hyperthyroidism in relation to the planned dosage].
    Moser E.
    Aktuelle Radiol; 1992 Jul 06; 2(4):179-87. PubMed ID: 1504115
    [Abstract] [Full Text] [Related]

  • 18. Graves' ophthalmopathy and 131I therapy.
    Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Mazzi B, Rocchi R, Barbesino G, Pinchera A.
    Q J Nucl Med; 1999 Dec 06; 43(4):307-12. PubMed ID: 10731781
    [Abstract] [Full Text] [Related]

  • 19. [Results of a risk adapted and functional radioiodine therapy in Graves' disease].
    Dunkelmann S, Neumann V, Staub U, Groth P, Künstner H, Schümichen C.
    Nuklearmedizin; 2005 Dec 06; 44(6):238-42. PubMed ID: 16400383
    [Abstract] [Full Text] [Related]

  • 20. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V, Voth E, Moka D, Schicha H.
    Nuklearmedizin; 2001 Aug 06; 40(4):111-5. PubMed ID: 11556200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.